Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sight Sciences, Inc.
This is a randomized study comparing viscodilation with the VISCO360 device to selective laser trabeculoplasty. Subjects with mild to moderate primary open-angle glaucoma undergo IOP-lowering medication washout at baseline and at Month 12. Subjects will be followed through Month 24.
Age
22–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosed with primary open-angle glaucoma (POAG) in the study eye.
Pseudophakic with Posterior Chamber IOL (PCIOL)
Able and willing to attend follow up visits for two years post-operative
Able and willing to sign informed consent
You may not be if
Phakia or aphakia
Previous glaucoma procedure with or without an implantable glaucoma device (including incisional surgery, ALT, iridectomy/iridotomy, etc.) \[Subjects with one prior SLT application (\>3 months prior to screening) or prior ECP (performed \> 12 months prior to screening) can be enrolled\].
Use of more than 3 ocular hypotensive medications (combination medications count as 2 medications)
Diagnosis of acute angle closure, traumatic, congenital, malignant, uveitic, pseudoexfoliative, pigmentary or neovascular glaucoma
Abnormal angle anatomy as determined by gonioscopy (e.g. peripheral anterior synechiae, rubeosis or other angle abnormalities)
Participation in any clinical trial ≤ 30 days prior to screening
Clareo Health | Safety and Effectiveness of the Sight Sciences VISCO™360 Versus SLT in Primary Open Angle Glaucoma
